Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial updates on its research and development (R&D) efforts and promising results from a Phase 1 dose-escalation study. Despite the recent surge, the stock remains down about 5% for the year, […]
RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class antibody-drug conjugate (ADC), at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) in Chicago. The study focuses on the efficacy and safety of RC88 in treating advanced solid […]
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates a new immunotherapy combination of REGN7075 and Libtayo (cemiplimab) targeting advanced solid tumors. This trial is among the first to show effectiveness in patients with microsatellite stable colorectal cancer (MSS CRC), a type traditionally resistant to immunotherapies. […]
In a significant stride for cancer treatment, Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company dedicated to addressing unmet needs in oncology, announced the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for NUV-1511. This marks a pivotal moment for the company as NUV-1511 is the first clinical candidate […]
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the treatment of advanced solid tumors and lymphomas. This was after Glenmark Specialty’s investigational new drug (IND) application for GRC 54276 was accepted by the US Food and Drug Administration (FDA). […]
Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. IK-930 is a TEAD inhibitor designed to target the Hippo signaling pathway. Earlier this year, IK-930 was granted the FDA orphan drug designation for the treatment of patients having malignant […]
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the Nasdaq, Turning Point Therapeutics is developing drug candidates that are said to target the highly common mutations related to oncogenesis. Its flagship asset is repotrectinib, which is a tyrosine kinase […]
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type of tumor found in the brain and spinal cord. The Chinese biopharma company is currently studying GLR2007 in a phase 1 clinical trial for the treatment of advanced solid tumors. […]
Bristol-Myers Squibb’s (BMS) latest clinical partnership with Israeli company Compugen is set to explore the efficacy of combining its leading cancer drug Opdivo (nivolumab) with Compugen’s COM701 in the treatment of advanced solid tumors. This collaboration will evaluate the combination of COM701, an anti-PVRIG antibody under investigation by Compugen, with Opdivo, a programmed death-1 (PD-1) […]
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ALKS 4230 in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab). This trial aims to explore the potential of this combination therapy in treating advanced solid tumors. ALKS 4230 is an […]